Abstract: This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.

Abstract: This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.

Abstract: Biomarkers, methods, assays, and kits are provided for predicting the progression of Barrett esophagus in a subject to esophageal cancer. The method can therefore also be used to select the appropriate treatment for a subject diagnosed with Barrett esophagus. Disclosed are methods for predicting the progression of Barrett esophagus in a subject to esophageal cancer. The method can therefore also be used to select the appropriate treatment for a subject diagnosed with Barrett esophagus. For example, the disclosed biomarkers, methods, assays, and kits can be used to predict the benefit of surgery, laser treatment, radiofrequency ablation, radiation therapy, chemotherapy, or any combination thereof for a subject diagnosed with Barrett esophagus based on whether they are predicted to progress to esophageal cancer.

Abstract: A biomarker is disclosed that can distinguish aggressive epithelial tumors in a tissue biopsy from, for example, normal, hyperplastic, and benign neoplastic tumors. The biomarker can also identify epithelial tumors that have become resistant to hormone therapy. Therefore, methods are disclosed for providing diagnosis and prognosis of a subject having, or suspected of having, an epithelial tumor, such as a prostate tumor.

Abstract: This invention relates to methods for treating subjects with breast cancer, based on tumor expression levels of chemokines.

Abstract: This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.

Abstract: This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.

Abstract: A biomarker is disclosed that can distinguish aggressive epithelial tumors in a tissue biopsy from, for example, normal, hyperplastic, and benign neoplastic tumors. The biomarker can also identify epithelial tumors that have become resistant to hormone therapy. Therefore, methods are disclosed for providing diagnosis and prognosis of a subject having, or suspected of having, an epithelial tumor, such as a prostate tumor.

Abstract: Biomarkers, methods, assays, and kits are provided for predicting the progression of Barrett esophagus in a subject to esophageal cancer. The method can therefore also be used to select the appropriate treatment for a subject diagnosed with Barrett esophagus. Disclosed are methods for predicting the progression of Barrett esophagus in a subject to esophageal cancer. The method can therefore also be used to select the appropriate treatment for a subject diagnosed with Barrett esophagus. For example, the disclosed biomarkers, methods, assays, and kits can be used to predict the benefit of surgery, laser treatment, radiofrequency ablation, radiation therapy, chemotherapy, or any combination thereof for a subject diagnosed with Barrett esophagus based on whether they are predicted to progress to esophageal cancer.

Abstract: This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.

Abstract: This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.

Abstract: The present invention relates to biomarkers for neoplasias such as high grade gliomas. The inventors have discovered that the overexpression of senescence associated genes (SAG) is associated with a poor prognosis in subjects with high grade gliomas. The present invention provides SAG biomarkers for predicting response to therapy for subjects having high grade glioma based on dividing the samples into high and low risk groups; diagnosing high grade glioma; monitoring progression of high grade glioma from one biological state to another; and determining efficacy of treatment for high grade gliomas.

Abstract: This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.

Abstract: The present invention relates to biomarkers for neoplasias such as high grade gliomas. The inventors have discovered that the overexpression of senescence associated genes (SAG) is associated with a poor prognosis in subjects with high grade gliomas. The present invention provides SAG biomarkers for predicting response to therapy for subjects having high grade glioma based on dividing the samples into high and low risk groups; diagnosing high grade glioma; monitoring progression of high grade glioma from one biological state to another; and determining efficacy of treatment for high grade gliomas.

Abstract: The invention includes methods for detecting the presence of a neoplastic condition by comparing a sample level of a BIF-1 to a reference, wherein a low level of BIF-1 in the sample correlates with the presence of a neoplastic condition. Another method involves determining the risk of relapse, tumor recurrence and/or metastasis by determining a sample level of a Bif-1 to a reference level of Bif-1, wherein low sample levels correlate with a likelihood of relapse, recurrence and/or metastasis. Yet another method includes detecting the presence of a pre-neoplastic condition, such as prostatic intraepithelial neoplasia. The method involves measuring a level of a Bif-1 in a sample and comparing the level of Bif-1 in the sample to a reference level of Bif-1. High levels of Bif-1 in the sample correlate with the presence of the pre-neoplastic condition.

Abstract: The invention includes methods for detecting the presence of a neoplastic condition by comparing a sample level of a BIF-1 to a reference, wherein a low level of BIF-1 in the sample correlates with the presence of a neoplastic condition. Another method involves determining the risk of relapse, tumor recurrence and/or metastasis by determining a sample level of a Bif-1 to a reference level of Bif-1, wherein low sample levels correlate with a likelihood of relapse, recurrence and/or metastasis. Yet another method includes detecting the presence of a pre-neoplastic condition, such as prostatic intraepithelial neoplasia. The method involves measuring a level of a Bif-1 in a sample and comparing the level of Bif-1 in the sample to a reference level of Bif-1. High levels of Bif-1 in the sample correlate with the presence of the pre-neoplastic condition.